JP7754846B2 - ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法 - Google Patents

ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法

Info

Publication number
JP7754846B2
JP7754846B2 JP2022567487A JP2022567487A JP7754846B2 JP 7754846 B2 JP7754846 B2 JP 7754846B2 JP 2022567487 A JP2022567487 A JP 2022567487A JP 2022567487 A JP2022567487 A JP 2022567487A JP 7754846 B2 JP7754846 B2 JP 7754846B2
Authority
JP
Japan
Prior art keywords
methyl
morpholinyl
pyrazol
dimethyl
pteridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022567487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525035A5 (enExample
JP2023525035A (ja
Inventor
チャバニウク，ララ・シー
ホッパー，ティモシー
ハウズ，ジョナサン・ビー
パンテレーエフ，ジェーン
レスクリオ，グウェンアエラ
サントラ，ビンセント
ワン，ハオシュエン
ホワイト，ライアン・ディー
ウォン，アリス・アール
ウー，ヨンウェイ
ボス，マクサンス
マンクーゾ，ジョン
フランゾーニ，アイバン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2023525035A publication Critical patent/JP2023525035A/ja
Publication of JP2023525035A5 publication Critical patent/JP2023525035A5/ja
Priority to JP2025166168A priority Critical patent/JP2026004465A/ja
Application granted granted Critical
Publication of JP7754846B2 publication Critical patent/JP7754846B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022567487A 2020-05-04 2021-05-04 ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法 Active JP7754846B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025166168A JP2026004465A (ja) 2020-05-04 2025-10-02 ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063019772P 2020-05-04 2020-05-04
US63/019,772 2020-05-04
PCT/US2021/070507 WO2021226629A1 (en) 2020-05-04 2021-05-04 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025166168A Division JP2026004465A (ja) 2020-05-04 2025-10-02 ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法

Publications (3)

Publication Number Publication Date
JP2023525035A JP2023525035A (ja) 2023-06-14
JP2023525035A5 JP2023525035A5 (enExample) 2024-05-17
JP7754846B2 true JP7754846B2 (ja) 2025-10-15

Family

ID=78468522

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022567487A Active JP7754846B2 (ja) 2020-05-04 2021-05-04 ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法
JP2025166168A Pending JP2026004465A (ja) 2020-05-04 2025-10-02 ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025166168A Pending JP2026004465A (ja) 2020-05-04 2025-10-02 ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法

Country Status (21)

Country Link
US (4) US11608344B2 (enExample)
EP (1) EP4146222A4 (enExample)
JP (2) JP7754846B2 (enExample)
KR (1) KR20230019822A (enExample)
CN (1) CN115867284A (enExample)
AR (1) AR122010A1 (enExample)
AU (1) AU2021266805A1 (enExample)
BR (1) BR112022022341A2 (enExample)
CA (1) CA3182105A1 (enExample)
CL (1) CL2022003047A1 (enExample)
CO (1) CO2022015930A2 (enExample)
CR (1) CR20220560A (enExample)
CU (1) CU24735B1 (enExample)
EC (1) ECSP22089527A (enExample)
IL (1) IL297833A (enExample)
JO (1) JOP20220296A1 (enExample)
MX (1) MX2022013842A (enExample)
PE (1) PE20230846A1 (enExample)
PH (1) PH12022552949A1 (enExample)
TW (1) TW202208355A (enExample)
WO (1) WO2021226629A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7741100B2 (ja) 2020-05-04 2025-09-17 アムジェン インコーポレイテッド ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
IL303261A (en) * 2020-12-04 2023-07-01 Vigil Neuroscience Inc Treatment of diseases associated with ATP-binding cassette transporter 1 dysfunction using TREM agonists
KR20240026911A (ko) * 2021-05-04 2024-02-29 비질 뉴로사이언스 인코포레이티드 골수성 세포 2 작용제 상에서 발현되는 유발 수용체로서의 헤테로고리 화합물 및 사용 방법
JP2024544553A (ja) * 2021-11-09 2024-12-03 ビジル・ニューロサイエンス・インコーポレイテッド ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法
AR127621A1 (es) * 2021-11-09 2024-02-14 Vigil Neuroscience Inc Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso
EP4430022A4 (en) * 2021-11-09 2025-09-10 Vigil Neuroscience Inc HETEROCYCLIC COMPOUNDS USED AS AGONISTS OF THE TRIGGER RECEPTOR EXPRESSED ON MYELOID CELLS 2 AND METHODS OF USE
WO2023192288A1 (en) * 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024233848A1 (en) * 2023-05-10 2024-11-14 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
CN121443608A (zh) * 2023-07-17 2026-01-30 穆纳治疗有限公司 Trem2调节剂
AR134657A1 (es) * 2023-12-12 2026-02-04 Vigil Neuroscience Inc Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso
AR134826A1 (es) 2024-01-04 2026-04-15 Muna Therapeutics Aps Moduladores de trem2
US12459953B2 (en) 2024-01-04 2025-11-04 Muna Therapeutics Aps TREM2 modulators
WO2025157993A1 (en) * 2024-01-24 2025-07-31 Muna Therapeutics Aps Trem2 modulators
WO2026024121A1 (en) * 2024-07-25 2026-01-29 Yuhan Corporation Bicyclic fused-ring derivative or salt thereof and pharmaceutical composition including the same
WO2026077862A1 (en) * 2024-10-07 2026-04-16 F. Hoffmann-La Roche Ag Trem2 agonists
WO2026077861A1 (en) * 2024-10-07 2026-04-16 F. Hoffmann-La Roche Ag Trem2 agonists

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531538A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用
JP2010526138A (ja) 2007-05-08 2010-07-29 アストラゼネカ・アクチエボラーグ ピロロピリミジン−７−オン誘導体とその薬剤としての使用
US20140342924A1 (en) 2011-06-02 2014-11-20 Almac Diagnostics Limited Molecular Diagnostic Test for Cancer
JP2020505454A (ja) 2017-01-17 2020-02-20 リヴァプール スクール オブ トロピカル メディスン 化合物
JP2023524806A (ja) 2020-05-04 2023-06-13 アムジェン インコーポレイテッド ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US2963481A (en) 1959-11-27 1960-12-06 Smith Kline French Lab 6-pteridinecarboxylic acid esters
DE2037693C3 (de) 1969-08-02 1975-01-16 Sumitomo Chemical Co., Ltd., Osaka (Japan) 1-Cyclopropylmethyl-2(1 H)-chinazolinonderivate
JPH05170744A (ja) * 1991-12-25 1993-07-09 Toray Dow Corning Silicone Co Ltd 含窒素芳香族複素環式化合物のアルキル化方法
JPH09510695A (ja) 1994-01-03 1997-10-28 エイシア・ファーマシュウティカルズ，インコーポレイテッド ８−アザ、６−アザ、および６，８−ジアザ−１，４−ジヒドロキノキサリン−２，３−ジオン類およびそのグリシン／ｎｍｄａリセプターに対するアンタゴニストとしての使用
PT1028950E (pt) 1997-10-28 2003-09-30 Warner Lambert Co Quinazolina-2,4-dionas 7-substituidas uteis como agentes antibacterianos
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
JP2004521892A (ja) 2000-12-20 2004-07-22 メルク　エンド　カムパニー　インコーポレーテッド （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤
JP2003005355A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
EP1558585B1 (en) 2002-10-04 2013-09-25 Prana Biotechnology Limited Neurologically-active compounds
GB0229281D0 (en) * 2002-12-16 2003-01-22 Novartis Ag Organic compounds
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
DE602004008312T2 (de) 2003-10-17 2008-04-17 4 Aza Ip Nv Heterocyclus-substituierte pteridin-derivate und ihre verwendung in der therapie
MXPA06005019A (es) * 2003-11-03 2006-07-06 Warner Lambert Co Nuevos inhibidores de la recaptacion de norpinefrina para el tratamiento de transtornos del sistema nervioso central.
UA83416C2 (en) 2004-02-13 2008-07-10 Баниу Фармасьютикал Ко., Лтд. Fused ring 4-oxopyrimidine derivative
WO2005087742A1 (en) * 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
WO2005095360A1 (en) 2004-04-02 2005-10-13 Prana Biotechnology Limited Neurologically-active compounds
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
KR100659088B1 (ko) 2005-07-15 2006-12-21 삼성에스디아이 주식회사 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자
WO2007038331A2 (en) 2005-09-23 2007-04-05 Smithkline Beecham Corporation Novel chemical compounds
US20090082349A1 (en) 2006-03-02 2009-03-26 Dashyant Dhanak Thiazolones for use as pi3 kinase inhibitors
US7855194B2 (en) * 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
WO2008003149A2 (en) 2006-07-06 2008-01-10 Gilead Sciences , Inc. Substituted pteridines for the treatment and prevention of viral infections
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
PT2057156T (pt) 2006-08-23 2017-05-04 Kudos Pharm Ltd Derivados de 2-metilmorfolina pirido-, pirazo- e pirimidopirimidina como inibidores de mtor
EP2142509B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
KR20100089082A (ko) 2007-10-15 2010-08-11 아스트라제네카 아베 조합 059
US20110098267A1 (en) 2008-02-07 2011-04-28 Synta Pharmaceuticals Corporation Topical formulations for the treatment of psoriasis
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
SMT202000257T1 (it) 2008-10-10 2020-07-08 Vm Discovery Inc Composizioni e metodi per il trattamento dei disturbi da uso di alcol, dolore e altre malattie
US20120022057A1 (en) 2009-03-18 2012-01-26 Schering Corporation Bicyclic compounds as inhibitors of diacyglycerol acyltransferase
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
EP2459558A2 (en) 2009-07-30 2012-06-06 Irm Llc Compounds and compositions as syk kinase inhibitors
WO2011014039A1 (en) 2009-07-31 2011-02-03 Rohm And Haas Electronic Materials Korea Ltd. Novel organic electroluminescent compounds and organic electroluminescent device using the same
WO2011037731A1 (en) 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
MX2012004846A (es) 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
MX2012010557A (es) * 2010-03-16 2012-10-05 Merck Patent Gmbh Morfolinilquinazolinas.
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
CN102887895B (zh) 2011-07-22 2016-08-24 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
KR101497124B1 (ko) 2011-11-28 2015-03-06 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 포함하는 유기전기소자 및 그 전자 장치
JP6283320B2 (ja) 2012-02-08 2018-02-21 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体
CN103374021B (zh) 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
WO2014146249A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
EP3027616B1 (en) 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Azaindole compounds as modulators of rorc
EP3080085B1 (en) 2013-12-09 2019-08-14 UCB Biopharma SPRL Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
KR20150080966A (ko) 2014-01-02 2015-07-13 최돈수 유기 전기 발광 소자용 발광 재료, 이를 이용한 유기 전기 발광 소자 및 유기 전기 발광 소자용 재료
KR20160060572A (ko) 2014-11-19 2016-05-30 주식회사 엠비케이 유기 발광 화합물, 잉크 조성물, 유기 발광 소자 및 전자 기기
SG11201708294YA (en) 2015-04-15 2017-11-29 Hoffmann La Roche Pyridopyrimidinones and their use as nmda receptor modulators
US10403826B2 (en) 2015-05-07 2019-09-03 Universal Display Corporation Organic electroluminescent materials and devices
EP3335254B1 (de) 2015-08-11 2020-04-08 Merck Patent GmbH Materialien für organische elektrolumineszenzvorrichtungen
WO2017031427A1 (en) 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
KR102606277B1 (ko) 2016-04-06 2023-11-27 삼성디스플레이 주식회사 유기 발광 소자
US10573692B2 (en) 2016-04-06 2020-02-25 Samsung Display Co., Ltd. Organic light-emitting device having a sealing thin film encapsulation portion
IL307931A (en) 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
WO2018067704A1 (en) 2016-10-04 2018-04-12 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
US11283028B2 (en) 2016-10-05 2022-03-22 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent compound and organic electroluminescent device comprising the same
WO2018108110A1 (zh) 2016-12-13 2018-06-21 广州华睿光电材料有限公司 金属有机配合物及其应用、混合物、有机电子器件
TW201843143A (zh) 2017-03-13 2018-12-16 德商麥克專利有限公司 含有芳基胺結構之化合物
WO2018169352A1 (en) 2017-03-16 2018-09-20 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent device
KR102335935B1 (ko) 2017-03-22 2021-12-06 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
WO2018183923A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Methods of using ehmt2 inhibitors
KR102389204B1 (ko) 2017-04-18 2022-04-21 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
WO2018204765A1 (en) 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
EP3638230A4 (en) 2017-06-13 2021-04-21 Commonwealth Scientific and Industrial Research Organisation Antiviral drugs
JPWO2019065516A1 (ja) 2017-09-26 2020-09-10 日本曹達株式会社 キノリン化合物および農園芸用殺菌剤
CA3081946A1 (en) 2017-10-18 2019-04-25 Epizyme, Inc. Methods of using ehmt2 inhibitors in preventing or treating blood disorders
US20210213014A1 (en) 2017-10-18 2021-07-15 Epizyme, Inc. Methods of using ehmt2 inhibitors in immunotherapies
CN108484680B (zh) 2018-01-31 2020-12-11 马鞍山南京大学高新技术研究院 一类双硫代芳环/芳杂环磷酸化合物作为辅助配体的铱配合物
MX2020010836A (es) * 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
US12453279B2 (en) 2018-08-22 2025-10-21 Universal Display Corporation Organic electroluminescent materials and devices
CN109265457A (zh) 2018-11-01 2019-01-25 中国药科大学 一种利用氧化芳构化构建吡啶并嘧啶二酮骨架的新方法
EP3966208A4 (en) 2019-05-10 2024-01-03 Antidote IP Holdings, LLC COMPOUNDS AND METHODS OF TREATING CANCER
CN110283171A (zh) 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用
US11820783B2 (en) 2019-09-06 2023-11-21 Universal Display Corporation Organic electroluminescent materials and devices
WO2021224802A1 (en) 2020-05-04 2021-11-11 Adama Makhteshim Ltd. Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4-dihydropyrimidin-2-one, and methods of use thereof
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
CN115515933A (zh) 2020-05-04 2022-12-23 武田药品工业株式会社 经管腔作用的n-(哌啶-4-基)苯甲酰胺衍生物
CN111454265B (zh) 2020-05-07 2021-08-24 宁波卢米蓝新材料有限公司 一种稠杂环化合物及其制备方法和应用
MX2024008594A (es) 2022-01-11 2024-09-23 Regeneron Pharma Variantes del receptor desencadenante expresado en células mieloides 2 (trem2) y usos de estas en el tratamiento de la enfermedad de alzheimer.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531538A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用
JP2010526138A (ja) 2007-05-08 2010-07-29 アストラゼネカ・アクチエボラーグ ピロロピリミジン−７−オン誘導体とその薬剤としての使用
US20140342924A1 (en) 2011-06-02 2014-11-20 Almac Diagnostics Limited Molecular Diagnostic Test for Cancer
JP2020505454A (ja) 2017-01-17 2020-02-20 リヴァプール スクール オブ トロピカル メディスン 化合物
JP2023524806A (ja) 2020-05-04 2023-06-13 アムジェン インコーポレイテッド ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法

Also Published As

Publication number Publication date
EP4146222A4 (en) 2024-10-09
US20230295170A1 (en) 2023-09-21
PH12022552949A1 (en) 2024-02-12
BR112022022341A2 (pt) 2023-01-10
TW202208355A (zh) 2022-03-01
AU2021266805A1 (en) 2022-12-01
CO2022015930A2 (es) 2023-01-26
CL2022003047A1 (es) 2023-07-14
US20230002390A1 (en) 2023-01-05
CR20220560A (es) 2023-08-18
US11912711B2 (en) 2024-02-27
US12428425B2 (en) 2025-09-30
US20240182477A1 (en) 2024-06-06
CN115867284A (zh) 2023-03-28
WO2021226629A1 (en) 2021-11-11
AR122010A1 (es) 2022-08-03
US20230295169A1 (en) 2023-09-21
CA3182105A1 (en) 2021-11-11
US11608344B2 (en) 2023-03-21
JP2023525035A (ja) 2023-06-14
JP2026004465A (ja) 2026-01-14
KR20230019822A (ko) 2023-02-09
MX2022013842A (es) 2023-02-22
CU24735B1 (es) 2025-02-07
PE20230846A1 (es) 2023-05-23
CU20220064A7 (es) 2023-06-13
JOP20220296A1 (ar) 2022-11-02
EP4146222A1 (en) 2023-03-15
IL297833A (en) 2023-01-01
US11884675B2 (en) 2024-01-30
ECSP22089527A (es) 2023-02-28

Similar Documents

Publication Publication Date Title
JP2026004465A (ja) ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法
JP7741100B2 (ja) ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法
TW202309029A (zh) 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
WO2023086800A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
KR20150138204A (ko) 피리디닐피라졸로퀴놀린 화합물
JP2024545591A (ja) ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法
WO2025136898A1 (en) Agonists of trem2 activity
WO2023086799A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists
WO2024233848A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2025128873A1 (en) Heterocyclic pyridinone compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
EA031038B1 (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
WO2025128848A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2024233847A2 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
EA052247B1 (ru) Гетероциклические соединения в качестве агонистов триггерного рецептора 2 миелоидных клеток и способы их применения
TWI924689B (zh) 嘧啶酮類化合物及其用途
HK40096431A (zh) 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251002

R150 Certificate of patent or registration of utility model

Ref document number: 7754846

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150